Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid HIV Treatment Initiation (RHAE) Pilot Study
NCT03512964Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dolutegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Johns Hopkins University. Primary endpoint: Number of Patients Who Receive Rapid HIV Treatment Initiation at 12 months. Started Nov 2016; status: completed.
02
Drugs
dolutegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03512964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512964.